Acquisition of Healthcare and Packaging Businesses in Indonesia
First written in FY2017-Q1. 6 of 15 entries say "Restated". Latest entry: FY2024.
No other company in this theme has enough history to compare yet.
- FY2024RestatedAnnual report
「In pharmaceutical and medical packaging materials, sales increased in Japan, but a substantial decline in sales at the Indonesian subsidiary resulted in lower sales for the business as a whole.」
Reconfirmed that the decline in sales at the Indonesian subsidiary remained a factor behind lower full-year sales in the Wellness Business. - FY2024-Q3Business-wide sales declined due to a substantial decrease in sales at the Indonesian subsidiaryAnnual report
「In pharmaceutical and medical packaging materials, sales increased in Japan, but a substantial decline in sales at the Indonesian subsidiary resulted in lower sales for the business as a whole.」
Although domestic sales increased, a substantial decline in sales at the Indonesian subsidiary resulted in a 2.2% year-on-year decrease in Wellness Business sales. - FY2024-Q2Indonesian subsidiary’s sales declined, while domestic sales provided supportAnnual report
「In pharmaceutical and medical packaging materials, sales declined at the Indonesian subsidiary, but increased domestic sales resulted in higher sales for the business as a whole.」
Although sales of pharmaceutical and medical packaging materials declined at the Indonesian subsidiary, growth in domestic sales resulted in higher sales for the Wellness Business as a whole. - FY2024-Q1RestatedAnnual report
「Sales increased in pharmaceutical and medical packaging materials, led by overseas subsidiaries.」
Reconfirmed that higher sales of pharmaceutical and medical packaging materials in the overseas business, including overseas subsidiaries in Indonesia and elsewhere, contributed to increased sales in the Wellness Business. - FY2023AdvancedAnnual report
「Sales of pharmaceutical and medical packaging materials increased substantially at overseas subsidiaries, while sales also increased for single-use bags and related products used in the manufacture of biopharmaceuticals and other products. As a result, sales were ¥27,058 million, up 12.8% year on year.」
Higher sales of pharmaceutical and medical packaging materials, including those of overseas subsidiaries in Indonesia and elsewhere, and of single-use bags and other products contributed to a 12.8% full-year increase in Wellness Business sales. - FY2023-Q3AdvancedAnnual report
「Sales of pharmaceutical and medical packaging materials increased substantially at overseas subsidiaries, while sales also increased for single-use bags and related products used in the manufacture of biopharmaceuticals and other products. As a result, sales were ¥20,269 million, up 16.4% year on year.」
Sales of pharmaceutical and medical packaging materials and single-use bags and other products increased at overseas subsidiaries, resulting in a 16.4% year-on-year increase in sales in the Wellness Business. - FY2022RestatedAnnual report
「Sales of pharmaceutical and medical packaging materials by overseas subsidiaries were substantially higher than in the same period of the previous year. In addition, sales of single-use bags for biopharmaceutical and other manufacturing applications and related products remained strong, resulting in higher revenue for the business as a whole.」
For the full year, reconfirmed the contribution to sales from pharmaceutical and medical packaging materials, including those of overseas subsidiaries in Indonesia and elsewhere, and strong sales of single-use bags and other products. - FY2022-Q3RestatedAnnual report
「Sales of pharmaceutical and medical packaging materials by overseas subsidiaries were substantially higher than in the same period of the previous year. In addition, sales of single-use bags for biopharmaceutical and other manufacturing applications and related products remained strong, resulting in higher revenue for the business as a whole.」
Reconfirmed the contribution to sales from pharmaceutical and medical packaging materials, including those of overseas subsidiaries in Indonesia and elsewhere, as well as strong sales of single-use bags and other products. - FY2019RestatedAnnual report
「Sales increased in pharmaceutical and medical packaging materials, reflecting the inclusion of sales from the Indonesian subsidiary.」
The Indonesian subsidiary’s contribution to sales following the acquisition was confirmed for the full year. - FY2018RestatedAnnual report
「Sales increased in pharmaceutical and medical packaging materials, reflecting the inclusion of sales from the Indonesian subsidiary.」
The Indonesian subsidiary’s contribution to sales following the acquisition was confirmed for the full year. - FY2018-Q3AdvancedAnnual report
「The performance of the Indonesian subsidiary acquired around the middle of last year in the Life Sciences business was reflected for the full period.」
The performance of the acquired Indonesian subsidiary was reflected for the full period, demonstrating a continuing contribution from operations following the acquisition. - FY2017AchievedAnnual report
「In accordance with the agreement, the shares were acquired on 1 August 2016, making the company a subsidiary.」
The acquisition and consolidation of the Indonesian Kingsford entity as a subsidiary were completed, and its subsidiaries were included in the scope of consolidation. - FY2017-Q3AdvancedAnnual report
「Revenue from the Indonesian consolidated subsidiary newly included in the scope of consolidation for pharmaceutical and medical packaging materials was added, while expanded sales of refillable stand-up pouches for household packaging also contributed, resulting in higher revenue for the business as a whole.」
The acquired Indonesian consolidated subsidiaries contributed to sales of pharmaceutical and medical packaging materials, demonstrating the operational benefits following the acquisition. - FY2017-Q2AdvancedAnnual report
「The Company’s consolidated subsidiary, PT Kingsford Holdings, additionally acquired interests in its subsidiaries PT Avesta Continental Pack and PT Indogravure from non-controlling shareholders.」
Following the consolidation of PT Kingsford Holdings as a subsidiary, additional interests in its two subsidiaries were acquired from non-controlling shareholders on 21 September 2016. The additional acquisition cost was US$21 million, expanding the Group’s ownership interests and the scope of consolidation. - FY2017-Q1First statedAnnual report
「To expand its healthcare business globally, the Company entered into an agreement on 23 June 2016 with Mitsui & Co. Asia Pacific Pte. Ltd., an overseas affiliate wholly owned by Mitsui & Co., Ltd., to jointly acquire all shares of PT Kingsford Holdings, an Indonesian company holding a 79.42% stake in PT Champion Pacific Indonesia Tbk, an Indonesian company that owns PT Avesta Continental Pack and PT Indogravure, both in Indonesia. The shares were acquired on 1 August 2016 from Champion Pacific Limited.」
To expand its healthcare business globally, jointly acquired Kingsford with a Mitsui-affiliated company. The acquisition price was US$20 million, the post-acquisition ownership interest was 60.00%, and the estimated amount including related costs was approximately US$39 million.